Market Data
Valentine’s Day has come, but it is never too late to focus on your heart health.
A groundbreaking new study has revealed that sotagliflozin, a drug recently approved to treat type 2 diabetes and kidney disease in people with additional cardiovascular risk factors, may also offer significant benefits for cardiovascular disease reduction. The study highlights the first SGLT inhibitor to combine the effects of SGLT1 and SGLT2 inhibitors, which block the transport of sodium and glucose across cell membranes, and could provide a game-changer for treating cardiovascular diseases associated with diabetes and kidney disease.
In the study, which was published in The Lancet Diabetes & Endocrinology, researchers found that sotagliflozin can significantly reduce the likelihood of heart attacks, strokes, and cardiovascular-related deaths. The stroke benefit observed in the trial was unique to sotagliflozin and was not previously reported in previous diabetes diabetes trials of selective SGLT2 inhibitors.
Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor; it specifically targets SGLT1 and SGLT2. These inhibitors block the functions of SGLT1 and SGLT2, which are enzyme complexes responsible for shifting sodium and glucose across the membranes of blood cells and tissues, respectively. By blocking these transporters, sotagliflozin can regulate blood sugar and control lipid concentrations, which may provide an alternative mechanism to reduce cardiovascular risks.
The study included 10,584 patients with chronic kidney disease, type 2 diabetes, and cardiovascular risk factors, randomly assigned to receive either sotagliflozin or a placebo, over an average of 16 months. The participants experienced a 23% reduction in mortality from heart attacks and strokes compared to the placebo group, with a significant reduction in cardiovascular-related deaths as well. This outcome is greater than what was observed in other diabetes diabetes treatments for these cardiovascular outcomes.
The dual effect of sotagliflozin by blocking both SGLT1 and SGLT2 tissues suggests a novel and unique mechanism for managing cardiovascular disease. SGLT1 is involved in transport in the kidney, gut, and blood, while SGLT2 is located in the kidney. By reducing both of these, sotagliflozin targets a broader range of tissues and can provide a more comprehensive reduction in cardiovascular risk.
Beyond its direct impact on blood pressure and sodium regulation, sotagliflozin may also present a potential bridge between diabetes and chronic kidney disease, further increasing the risk of cardiovascular events. Over 384 million Americans are affected by diabetes, while about 38 million are also diagnosed with chronic kidney disease. The interplay between these twoAddressing both conditions may increase the risk of stroke and heart disease, as both are linked to impaired blood vessel function.
The study’s findings suggest that sotagliflozin could serve as a new first-line treatment for diabetes patients and those with chronic kidney disease experiencing cardiovascular risks. It may eliminate Kenneth diabetes and prescribe cardiovascular omega-3 fatty acids, such as resalibrate 1 omega-3. According to Dr. Deepak Bhatt, a study chair from Mount Sinai Fuster Heart Hospital and the Icahn School of Medicine at Mount Sinai, the benefits are unique to sotagliflozin.
This breakthrough in cardiovascular therapy could empower healthcare professionals to offer targeted lifestyle modifications to prevent heart disease and strokes, bypassing the need for complex and costly diabetes diabetes therapies. The women’s perspective, including their reliance on diet and exercise, suggests that sotagliflozin may be a more sustainable approach to managing cardiovascular events in diabetes patients.
